Molecular Characterization of Neuroendocrine-like Bladder Cancer.
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols
/ adverse effects
Biomarkers, Tumor
Carcinoma, Neuroendocrine
/ genetics
Computational Biology
Female
Gene Expression Profiling
Humans
Immunohistochemistry
Male
Middle Aged
Neoplasm Metastasis
Neoplasm Staging
Prognosis
Reproducibility of Results
Transcriptome
Treatment Outcome
Urinary Bladder Neoplasms
/ genetics
Journal
Clinical cancer research : an official journal of the American Association for Cancer Research
ISSN: 1557-3265
Titre abrégé: Clin Cancer Res
Pays: United States
ID NLM: 9502500
Informations de publication
Date de publication:
01 07 2019
01 07 2019
Historique:
received:
31
10
2018
revised:
21
01
2019
accepted:
26
03
2019
pubmed:
7
4
2019
medline:
6
8
2020
entrez:
7
4
2019
Statut:
ppublish
Résumé
Neuroendocrine (NE) bladder carcinoma is a rare and aggressive variant. Molecular subtyping studies have found that 5% to 15% of muscle-invasive bladder cancer (MIBC) have transcriptomic patterns consistent with NE bladder cancer in the absence of NE histology. The clinical implications of this NE-like subtype have not been explored in depth. Transcriptome-wide expression profiles were generated for MIBC collected from 7 institutions and clinical-use of Decipher Bladder. Using unsupervised clustering, we generated a clustering solution on a prospective training cohort (PTC; In the training cohort (PTC), hierarchical clustering using an 84-gene panel showed a cluster of 8 patients (4.6%) with highly heterogeneous expression of NE markers in the absence of basal or luminal marker expression. NE-like tumors were identified in 1% to 6.6% of cases in validation cohorts. Patients with NE-like tumors had significantly worse 1-year progression-free survival (65% NE-like vs. 82% overall; A single-patient classifier was developed that identifies patients with histologic urothelial cancer harboring a NE transcriptomic profile. These tumors represent a high-risk subgroup of MIBC, which may require different treatment.
Identifiants
pubmed: 30952638
pii: 1078-0432.CCR-18-3558
doi: 10.1158/1078-0432.CCR-18-3558
doi:
Substances chimiques
Biomarkers, Tumor
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
3908-3920Informations de copyright
©2019 American Association for Cancer Research.